Advancing Subcutaneous Diuretic Therapy for Hea...

By João L. Carapinha

April 28, 2026

Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Mark...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program f...
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Mar...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and ...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies
Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovas...
Zanidatamab Biliary Cancer Therapy: Advancing Targeted Treatment for HER2-Pos...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence...
Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark
Amyloid-Beta Treatment Impact: Limited Clinical Benefits and Increased Risks ...
Escalating Public Spending: Semaglutide Off-Label Use Sparks €250 Million Fra...